Ethical Issues of Using Gene Therapy in the Treatment of AMD

Recruiting now

Conditions studied: Exudative Age-related Macular Degeneration

In brief

The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.

Key facts

Study ID

NCT07004361

Run by

Nantes University Hospital

People needed

30

Starts

2025-07-01

Expected to finish

2026-12-01

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with exsudative AMD, male female >18 years Patients for whom the doctor could consider gene therapy.

You may not qualify if…

• Patients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.

Where it is running

• CHU Nantes - Ophthalmology Department — Nantes, Nantes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.